Featured Research

from universities, journals, and other organizations

Killing Kindlin-3 to cure breast cancer: 'Blood' protein implicated

Date:
May 1, 2014
Source:
Federation of American Societies for Experimental Biology
Summary:
A protein believed to be limited to the hematopoietic system, called Kindlin-3, has been identified as a major player in both the formation and spread of breast cancer to other organs. This discovery could open the door to an entirely new class of breast cancer drugs that targets this protein's newly found activity.

A protein believed to be limited to the hematopoietic system, called Kindlin-3, has been identified as a major player in both the formation and spread of breast cancer to other organs. This discovery, published in the May 2014 issue of The FASEB Journal, could open the door to an entirely new class of breast cancer drugs that targets this protein's newly found activity.

Related Articles


"Kill Kindlin-3 to cure cancer," said Elzbieta Pluskota, Ph.D., a researcher involved in the work from the Department of Molecular Cardiology at the Cleveland Clinic Lerner Research Institute in Cleveland, Ohio. "Let our moms, wives, sisters and daughters live long and healthy lives."

To make this discovery, Pluskota and colleagues searched gene expression databases to identify gene products that are elevated in breast cancer, and therefore, likely candidates to be involved in the disease progression. They found that Kindlin-3 expression levels are significantly elevated in breast cancer tumors when compared to the adjacent normal mammary tissue. In fact, Kindlin-3 was in the top 3 percent of gene products elevated in breast cancer cells. Then the scientists studied two groups of animal models. The first group (control group) was implanted with cancer cells that did not express Kindlin-3, while the second group (experimental group) received cancer cells that were engineered to express high levels of Kindlin-3. The experimental group developed bigger tumors that grew significantly faster, metastasized more, and were more angiogenic than the control group. Further biochemical analyses showed that Kindlin-3 enhanced the production and secretion of VEGF, a molecule that is required for the formation of new blood vessels. This study also identified a previously unknown function of Kindlin-3; the regulation of epithelial-mesenchymal transition, a process required for cancer cells to become mobile and invasive.

"Just when scientists thought they knew all there was to know about Kindlin-3, we now learn that this protein has mostly been flying under the radar in breast cancer research all along," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This discovery puts us on a path toward developing treatments, which slow, stop or reverse the progression of some of the most aggressive breast cancers."


Story Source:

The above story is based on materials provided by Federation of American Societies for Experimental Biology. Note: Materials may be edited for content and length.


Journal Reference:

  1. K. Sossey-Alaoui, E. Pluskota, G. Davuluri, K. Bialkowska, M. Das, D. Szpak, D. J. Lindner, E. Downs-Kelly, C. L. Thompson, E. F. Plow. Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. The FASEB Journal, 2014; 28 (5): 2260 DOI: 10.1096/fj.13-244004

Cite This Page:

Federation of American Societies for Experimental Biology. "Killing Kindlin-3 to cure breast cancer: 'Blood' protein implicated." ScienceDaily. ScienceDaily, 1 May 2014. <www.sciencedaily.com/releases/2014/05/140501111728.htm>.
Federation of American Societies for Experimental Biology. (2014, May 1). Killing Kindlin-3 to cure breast cancer: 'Blood' protein implicated. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2014/05/140501111728.htm
Federation of American Societies for Experimental Biology. "Killing Kindlin-3 to cure breast cancer: 'Blood' protein implicated." ScienceDaily. www.sciencedaily.com/releases/2014/05/140501111728.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins